BMJ, doi: 10.1136/bmj.39098.583356.55, (Published 8 February 2007)

RESEARCH

Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial

I A Campbell ^1*, D P Bentley ¹, R J Prescott ², P A Routledge ¹, H G M Shetty ³, I J Williamson ⁴

¹ Llandough Hospital, Llandough, Cardiff CF64 2XX
² Department of Public Health Sciences, University of Edinburgh, Edinburgh
³ University Hospital of Wales, Cardiff
⁴ Royal Gwent Hospital, Newport, Gwent

^* Correspondence to: ian.campbell{at}cardiffandvale.wales.nhs.uk.

Objective To determine the optimum duration of oral anticoagulant therapy after an episode of deep vein thrombosis or pulmonary embolism, or both.

Design Multicentre, prospective, randomised study with follow-up for one year.

Setting 46 hospitals in United Kingdom.

Participants Patients aged 18 with deep vein thrombosis or pulmonary embolism, or both.

Interventions Three (n=369) or six months (n=380) of anticoagulation with heparin for five days accompanied and followed by warfarin, with a target international normalised ratio of 2.0-3.5.

Main outcome measures Death from deep vein thrombosis or pulmonary embolism; failure to resolve, extension, recurrence of during treatment; recurrence after treatment; and major haemorrhage during treatment.

Results In the patients allocated to three months' treatment two died from deep vein thrombosis or pulmonary embolism during or after treatment, compared with three in the six month group. During treatment deep vein thrombosis or pulmonary embolism failed to resolve, extended, or recurred in six patients in the three month group without fatal consequences, compared with 10 in the six month group. After treatment there were 23 non-fatal recurrences in the three month group and 16 in the six month group. Fatal and non-fatal deep vein thrombosis or pulmonary embolism during treatment, and after treatment thus occurred in 31(8%) of those who had received three months' anticoagulation compared with 29 (8%) of those who had received six months' (P=0.80, 95% confidence interval for difference -3.1% to 4.7%). There were no fatal haemorrhages during treatment but there were eight major haemorrhages in those treated for six months and none in those treated for three months (P=0.008, -3.5% to -0.7%). Thus 31 (8%) of the patients receiving three months' anticoagulation experienced adverse outcomes as a result of deep vein thrombosis or pulmonary embolism or its treatment compared with 35 (9%) of those receiving six months' (P=0.79, -4.9% to 3.2%).

Conclusion For patients in the UK with deep vein thrombosis or pulmonary embolism and no known risk factors for recurrence, there seems to be little, if any, advantage in increasing the duration of anticoagulation from three to six months. Any possible advantage would be small and would need to be judged against the increased risk of haemorrhage associated with the longer duration of treatment with warfarin.

Trial registration Clinical Trials NCT00365950.

---

(Accepted 3 January 2007)
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Evidence based parenting and anticoagulating

Douglas Kamerow
BMJ 2007 334: -a0-a. [Extract] [Full Text]

Anticoagulation for venous thromboembolism

John W Eikelboom, Jeffrey S Ginsberg, and Jack Hirsh
BMJ 2007 334: 645. [Extract] [Full Text] [PDF]

Testing pitfalls and summary of guidance in lipid management

W Stuart A Smellie
BMJ 2006 333: 83-86. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., Comerota, A. J. (2008). Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 454S-545S [Abstract] [Full text]  
• Tapson, V. F. (2008). Acute Pulmonary Embolism. NEJM 358: 1037-1052 [Full text]  
• Kamphuisen, P. W (2007). 6 or 3 months of anticoagulant therapy did not differ for treatment failure in patients with DVT, PE, or both. Evid. Based Med. 12: 143-143 [Full text]  
• (2007). How Long to Treat Venous Thromboembolism?. JWatch General 2007: 7-7 [Full text]  
• Eikelboom, J. W, Ginsberg, J. S, Hirsh, J. (2007). Anticoagulation for venous thromboembolism. BMJ 334: 645-645 [Full text]  
• Heit, J. A. (2007). Thrombophilia: Common Questions on Laboratory Assessment and Management. ASH Education Book 2007: 127-135 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

With no known risk factors for recurrence

Anil Kumar Chawla
bmj.com, 10 Feb 2007 [Full text]

The site of DVT

GAMAL B ALFITORI
bmj.com, 15 Feb 2007 [Full text]

One year follow up not enough

Anil K Chawla
bmj.com, 15 Feb 2007 [Full text]

Potentially biased assessment of bleeding with 6 versus 3 months of anticoagulation for venous thromboembolism

Clive Kearon
bmj.com, 16 Feb 2007 [Full text]

Optimal duration for anticoagulation in VTE

Nosa A Akporehwe, et al.
bmj.com, 19 Feb 2007 [Full text]

The study is underpowered and cases are poorly representative of those commonly entountered in clinical practice

Luca Puccetti
bmj.com, 22 Feb 2007 [Full text]

How long the anticoagulation therapy?

Fulvio Pomero, et al.
bmj.com, 23 Feb 2007 [Full text]

Anticoagulation beyond 3 months in idiopathic venous thromboembolism

Diana C Ferreira, et al.
bmj.com, 10 Mar 2007 [Full text]

Duration of Anticoagulation Therapy

Sameer Chadha, et al.
bmj.com, 12 Mar 2007 [Full text]

D-dimers can be a better guide for the length of anticoagulation

Mohammed A M SIDDIQUI
bmj.com, 29 Mar 2007 [Full text]

Physician vs GP management of venous thrombosis

Andrew Mahony, et al.
bmj.com, 3 Apr 2007 [Full text]

Methodological issues keep the 3 versus 6 month treatment debate unresolved

Amit Patel
bmj.com, 5 Apr 2007 [Full text]